Navigation Links
Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
Date:1/12/2009

volve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2007 and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
2. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
5. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
6. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
7. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
8. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Latanoprost ... Developed by Pharmacia & Upjohn in 1995, ... effectively reduces intraocular pressure. As the first pressure- ... trade name of Xalatan) entered China ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
(Date:8/28/2015)... SEOUL, South Korea , Aug. 28, 2015 /PRNewswire/ ... Chungbuk National University and Dr. Ra from Biostar ... , Confirmed 30% increase of lifespan through multiple ... cognitive function, physical vitality, and life expectancy found ... Researchers in Korea have determined the possibility that adult ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Inc. (Nasdaq: CRTX ) today announced that it ... Thursday, November 4, 2010, to discuss its financial results for ... results are expected to be released on Thursday, November 4, ... in the live conference call, please dial 866-804-6927 (U.S. callers) ...
... See video from AstraZeneca at: ... Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue ... at constant exchange rates (CER) to $7,898 ... for Crestor, Symbicort and Seroquel XR. Revenue ...
Cached Medicine Technology:Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call 2Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call 3
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ProDrop Particles ... . Each preset contains 15 seconds of unique footage that users can shrink and ... fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, and ...
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
(Date:8/28/2015)... New Port Richey, FL (PRWEB) , ... August 28, 2015 , ... ... that while many potential workers are qualified for the position they are applying for, ... work. Because of this, many employers are considering altering drug testing policies in order ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for ... subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk ... believe that together, a difference can be made. Walkers can participate in the cause ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2
... Texas Health Care Association Urges Clinton, Obama, McCain, ... AUSTIN, Texas, Feb. 12 As Democratic,presidential ... today to compete in the increasingly important March ... urged the major,presidential candidates of both parties to ...
... FORT BELVOIR, Va., Feb. 12 Ehmke,Manufacturing ... recipients when,the Defense Logistics Agency honored 23 ... its Business Alliance Awards., Ehmke received ... Award in,the historically underutilized business (HUB) zone, ...
... Feb. 12 XTENT, Inc.,(Nasdaq: XTNT ) announced ... market close on Tuesday, February 19, 2008. The company ... p.m., Pacific Time (5 p.m. Eastern Time).,The call will ... Chief,Executive Officer, and Tim Kahlenberg, Chief Financial Officer., ...
... Spotlights Sector,s Leadership in Improving,Transparency, Expanding Public Disclosure, ... a,statement by Alan G. Rosenbloom, President of the ... for Medicare and Medicaid Services,(CMS) release today of ... in,need of improvement:, "Nursing home providers have ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that ... Mid-Cap Growth Conference on Friday, February 15,2008 at approximately ... is scheduled to be webcast live and may be ... . The webcast will,be available for 30 days following ...
... may cause women with ductal carcinoma in situ (DCIS), ... overestimate their risk of recurrence or dying from breast ... Cancer Institute in Boston. , "Although DCIS typically is ... inaccurate risk perceptions," said Ann Partridge, MD, MPH, the ...
Cached Medicine News:Health News:Growing Importance of March 4 Texas Primary Requires 2008 Presidential Candidates to Better Address Eldercare Financing Issues 2Health News:Defense Logistics Agency Recognizes Ehmke Manufacturing Company 2Health News:Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference 2Health News:Anxiety linked to newly diagnosed DCIS patients' overestimation of breast cancer risks 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Wide 1 mm x 3 mm smooth platform. Serrated handle with polished finish. Most popular size or model....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
Fine 2 mm wide platform. Cross action serrated handle with metal tip guard. Polished finish....
Medicine Products: